Faecal microbiota transplants aim to restore a healthy balance of bacteria in the gut of people who have recurrent C. difficile infections by introducing enteric bacteria from the faeces of healthy donors. C. difficile is a bacterium that lives harmlessly in the gut of approximately 3% of healthy people.
 
Status In progress
Process MT
ID number 566

Provisional Schedule

Stakeholder registration opens 11 August 2021
Scope published 22 September 2021
Committee meeting: 1 18 March 2022
Draft guidance: 1 08 April 2022 - 11 May 2022
Committee meeting: 2 17 June 2022
Resolution 18 July 2022
Expected publication 30 August 2022

Project Team

Project lead Charlotte Pelekanou

Email enquiries

Stakeholders

External assessment group YHEC
Others Association of British Healthcare Industries (ABHI)
  Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
  Boston Scientific
  Department of Health and Social Care
  Devices for Dignity
  Greater Manchester Health & Social Care Partnership
  Healthcare Improvement Scotland
  HealthTech Alliance
  Johnson & Johnson Medical Ltd
  Medical Technology Group
  Medicines and Healthcare Products Regulatory Agency
  University of Manchester Wounds Research Group
  NHS England
  The British In Vitro Diagnostics Association (BIVDA)
  NHS Digital

For further information on how we develop guidance, please see our page about NICE medical technologies guidance